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Chemotherapy-induced febrile neutropenia is costly in both financial and human terms. The associated costs can be reduced
substantially through the development and implementation of national policies and locally agreed protocols for the prevention and
management of febrile neutropenia. Patients, the NHS, healthcare professionals and the broader community all stand to benefit from
a commitment to effective management of this common and predictable side effect of some chemotherapy regimens for early-stage
breast cancer.
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Febrile neutropenia (FN) is a serious complication of chemo-
therapy for early-stage breast cancer, with significant morbidity
and mortality, and important implications for patients and
healthcare resources.
It is estimated that 95% of women diagnosed with breast cancer
in the UK have early-stage disease (43000 women/year) (CRUK,
2009), 13000 (30%) of whom will be node-positive (Verschraegen
et al, 2005). Around 9000 women per year with node-positive
early-stage breast cancer receive chemotherapy (CRUK, 2009). On
the basis of the regimens used and their reported FN rates, the
incidence of FN among women receiving chemotherapy for node-
positive early-stage breast cancer is estimated at around 16%
(Poole et al, 2006; Roche ´ et al, 2006; Ali et al, 2008; Head et al,
2008; Scaife et al, 2008; Zaman et al, 2008). Therefore, it is
conservatively estimated that more than 1000 women each year
receiving chemotherapy for node-positive breast cancer will have
an episode of FN (Poole et al, 2006; Roche ´ et al, 2006; Ali et al,
2008; Head et al, 2008; Scaife et al, 2008; Zaman et al, 2008).
FN requires hospitalisation and treatment with intravenous
antibiotics, and has a negative impact on patients’ quality of life
(Moore and Crom, 2006). Furthermore, the development of FN
may lead to a decision to reduce or delay the patient’s subsequent
chemotherapy dose, which can undermine treatment outcomes,
including overall survival, particularly in the adjuvant setting
(Bonadonna et al, 1995; Lyman et al, 2005; Chirivella et al, 2006).
The effective management of FN embraces both prevention of
the condition with prophylactic measures, such as the use of
granulocyte colony-stimulating factors (G-CSF) and/or antibiotics,
and the appropriate management of febrile neutropenic events,
notably neutropenic sepsis.
Other articles in this supplement look in detail at FN prevention
and management (Kelly and Wheatley, 2009; Cullen and Baijal,
2009). In this article, we consider the impact of prophylactic and
management interventions on patients, the NHS, healthcare
professionals and the broader community.
IMPACT OF FN PROPHYLAXIS
If a patient develops FN, the direct and indirect costs to the
individual, the NHS and the economy are substantial. The costs
derive from a range of factors, including hospitalisation for
treatment of FN, significant morbidity and mortality, financial
losses for patients and their families/carers and reduced health-
related quality of life (Moore and Crom, 2006; Gridelli et al, 2007).
These costs also undermine public confidence in cancer services
(Figure 1).
Furthermore, the loss of productivity associated with hospita-
lisation and morbidity has a detrimental impact on the economy.
By preventing FN through the use of appropriate prophylactic
measures, some of these costs may be avoided (Figure 2), leading
to improved quality of life and treatment efficacy for patients,
reduced healthcare costs and greater predictability of care needs
(Kuderer et al, 2006).
As discussed by Trueman (2009) in this supplement, analysis of
the cost effectiveness of prophylaxis with G-CSF is fraught with
difficulty, because of a lack of consistency across clinical trials and
because of the problems faced when transferring pharmacoeco-
nomic considerations from one healthcare system to another.
However, various economic models suggest that primary prophy-
laxis with G-CSF may be cost-effective when the risk of FN exceeds
specific thresholds, for example, 20% (Lyman et al, 1998), 16%
(Eldar-Lissai et al, 2008) or 18% (Dale et al, 2006).
IMPACT OF MANAGEMENT OF FN EVENTS
Inadequacies in the management of FN in the UK, and several key
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Outcome and Death (NCEPOD, 2008). Such inadequacies have a
negative impact on patients, and on the perception of cancer care
by the broader NHS and the public. This perception leads, in turn,
to reduced confidence in the NHS, which, coupled with the added
stress caused by potentially avoidable additional hospital visits and
extended hospitalisation, may affect patients’ willingness to
undergo further treatment (Fortner et al, 2002).
In response to the findings of NCEPOD and a report from
the National Cancer Peer Review Network (NCPRN, 2008), the
National Chemotherapy Advisory Group has issued recommenda-
tions for improving the management of FN (NCAG, 2009). The
advice is aimed not only at chemotherapy providers but also at any
hospital with acute facilities to which patients with possible
chemotherapy side effects may present. The implementation of the
recommendations is expected to benefit patients, the NHS and
healthcare professionals.
Benefits for patients
Effective management of FN events may have a significant impact
on patients’ quality of life, morbidity, mortality, long-term survival
and finances.
The development of FN has been shown to correlate with lower
quality-of-life scores (Okon et al, 2002) and an increase in the
incidence and severity of chemotherapy-related side effects such as
mucositis, abdominal pain and diarrhoea, anorexia and fatigue
(Glaspy et al, 2001).
The mortality rates associated with FN range from 2 to 21%
(Smith et al, 2006; Herbst et al, 2008) – the higher rates are often
seen in patients with comorbidities, which may be age-related, or
in patients with poor performance status, including those with
advanced cancer and undergoing palliative chemotherapy (Lyman
et al, 2005).
FN often results in chemotherapy dose reductions and dose
delays (Leonard et al, 2003), and the resulting reduction in
chemotherapy dose intensity can have a significant negative
impact on clinical outcome, notably survival (Bonadonna et al,
1995; Chirivella et al, 2006). Indeed, patients who receive less than
65% of their planned dose have been shown to have survival rates
similar to those who receive no chemotherapy at all (Bonadonna
et al, 1995). Such dose reductions are common in the absence
of clear local policy on primary prevention of neutropenia in
patients undergoing treatment with curative intent. However, dose
reductions (and lower starting doses) may be advisable in certain
high-risk patients, including those with comorbidities or poor per-
formance status and those undergoing palliative chemotherapy,
who are also susceptible to the non-haematological toxicities
associated with chemotherapy (Lyman et al, 2005; NCEPOD, 2008).
FN disrupts normal life activities such as childcare and
employment (Moore and Crom, 2006), and thus has financial
and social implications for patients and their families.
Benefits for the NHS
FN imposes a significant burden on NHS finances and resources –
a single episode is estimated to cost the NHS d3582 (Holmes et al,
2004). The major economic impact is related to hospitalisation; the
average length of hospital stay is 6–8 days (Kuderer et al, 2006).
Hospitalisation puts patients at risk of developing further
complications, such as hospital-acquired infections and throm-
boembolic events, which add to the overall cost of FN.
Inadequate admission pathways and a lack of management
protocols lead to inappropriate placement of patients, inefficient
and inappropriate use of healthcare resources, treatment delays
and prolonged hospitalisation (NCEPOD, 2008). Implementation
of network policies, and locally agreed hospital admission path-
ways, together with the availability of clear management protocols,
should lead to patients with FN being admitted efficiently, under
the care of the appropriate healthcare professional and receiving
the appropriate treatment in a timely manner (NCEPOD, 2008).
Such practices will reduce healthcare costs, encourage appropriate
and efficient use of NHS resources and reduce the costs associated
with prolonged stay, morbidity and mortality.
Benefits for healthcare professionals
As a result of locally agreed and implemented policies for the
management of FN, healthcare professionals will become more
confident in their ability to manage patients with the condition,
and the public’s confidence in healthcare services will be
enhanced. Achieving this goal will require education of all
healthcare professionals, including those not directly involved in
frontline cancer care, both at a national and local level (NCEPOD,
2008). It will also require a regular, systematic audit of the
complications of chemotherapy, with review at a local and network
level forming part of the appraisal and education of healthcare
professionals (NCEPOD, 2008).
Chemotherapy can do more harm
than good, study suggests
Hundreds of cancer patient
Telegraph November 11, 2008
TIMES November 12, 2008
deaths ‘caused by chemotherapy’
Figure 1 National headlines reflect how public confidence in cancer
services is undermined.
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Figure 2 Short-term and long-term effects of FN prevention.
Table 1 Failures in the management of patients admitted with
neutropenic sepsis (NCEPOD, 2008)
Organisational failures Clinical failures
Lack of treatment policy in emergency
departments
Delayed admission
Clinician unaware of treatment policy Failure of junior doctors to make the
diagnosis
Patient managed in an inappropriate
care setting
Lack of awareness that patients without
a fever may still have FN
Only occasional oncology visit to
cancer unit in a district general hospital
Lack of early assessment by senior staff
Delayed resuscitation
Delayed prescription and
administration of antibiotics
Failure to adhere to local antibiotics
policy
Delayed transfer to intensive care
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Several groups have conducted audits in patients receiving chemo-
therapy, looking at the rates of FN, dose delays and dose reductions,
and the effects of adding prophylactic G-CSF and/or antibiotics
(Ali et al, 2008; Head et al, 2008; Scaife et al, 2008). The results of
three audits of patients receiving FEC-T (fluorouracil, epirubicin and
cyclophosphamide followed by docetaxel) or TAC (docetaxel,
doxorubicin and cyclophosphamide) were presented at the 2008
National Cancer Research Institute Cancer Conference, which took
place in Birmingham. The findings are summarised in Tables 2–4. All
three groups plan to re-audit their practice following the introduction
of primary prophylaxis with G-CSF with or without antibiotics in the
same groups of patients. The findings of these re-audits may prove
useful in guiding the management of FN in the future.
CONCLUSION
FN is a significant complication of chemotherapy treatment from
the point of view of patients, healthcare professionals and the NHS.
Reports of serious inadequacies in the management of FN in the
UK (NCEPOD, 2008; NCPRN, 2008) have led to recommendations
(NCAG, 2009) for robust systems to be put in place to admit and
manage patients with FN. The implementation and audit of such
systems will have an impact not only on individual patients but
also on healthcare professionals and the wider NHS.
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